Pre-Open Stock Movers:

Axovant Gene Therapies Ltd. (Nasdaq: AXGT) 39.5% LOWER; announced program updates to be presented as part of its virtual R&D Day on Friday, October 30, 2020 at 11:30 AM Eastern time, for the Companys AXO-Lenti-PD gene therapy for Parkinsons disease. Trial pushed back.

Columbia Sportswear (NASDAQ: COLM) 16.4% LOWER; reported Q3 EPS of $0.94, $0.22 worse than the analyst estimate of $1.16. Revenue for the quarter came in at $701.1 million versus the consensus estimate of $767.13 million. Columbia Sportswear sees Q4 2020 EPS of $1.07-$1.32, versus the consensus of $1.59. Columbia Sportswear sees Q4 2020 revenue of $850-880 million, versus the consensus of $914.4 million.

Twitter (NYSE: TWTR) 16.4% LOWER; reported Q3 EPS of $0.04, $0.02 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $936 million versus the consensus estimate of $777.15 million. Average mDAU was 187 million for Q3, compared to 145 million in the same period of the previous year and compared to 186 million in the previous quarter. Average US mDAU was 36 million for Q3, compared to 30 million in the same period of the previous year and compared to 36 million in the previous quarter.

Equillium, Inc. (Nasdaq: EQ) 16% HIGHER; announced that it has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin a Phase 3 clinical trial, named EQUINOX, evaluating itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome (ARDS). Equillium plans to start enrolling patients during the fourth quarter of 2020, and initial clinical data is expected mid-year 2021. The FDA has indicated that the trial, if it meets its primary and key secondary endpoints, may be sufficient to support regulatory filing of a Biologic License Application (BLA).

Trupanion (NASDAQ: TRUP) 15.2% HIGHER; reported Q3 EPS of ($0.07), $0.03 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $130.1 million versus the consensus estimate of $126.53 million.

Plantronics (NYSE: PLT) 14.9% HIGHER; reported Q2 EPS of $0.93, $0.45 better than the analyst estimate of $0.48. Revenue for the quarter came in at $411 million versus the consensus estimate of $375.74 million. Plantronics sees Q3 2021 EPS of $0.85-$1.05, versus the consensus of $0.47. Plantronics sees Q3 2021 revenue of $417-477 million, versus the consensus of $381.2 million.

Trupanion, Inc. (Nasdaq: TRUP) 13.1% HIGHER; Aflac Incorporated (NYSE: AFL), a Fortune 200 company that helps provide protection to more than 50 million people in Japan and the U.S., and Trupanion, Inc. (Nasdaq: TRUP), a leader in medical insurance for cats and dogs, are pleased to have entered into an exclusive alliance agreement to sell pet insurance in worksites across the U.S. This alliance will leverage Aflac's strong brand and broad U.S. worksite distribution network, including its digital Consumer Markets channel, and Trupanion's expertise and leadership in pet insurance. The companies also have agreed to explore potential opportunities in Japan's growing pet insurance market. In connection with the alliance agreement, Aflac will purchase an approximate 9% stake in Trupanion to further drive alignment.

Flex Ltd. (NASDAQ: FLEX) 12.6% HIGHER; reported Q2 EPS of $0.36, $0.09 better than the analyst estimate of $0.27. Revenue for the quarter came in at $6 billion versus the consensus estimate of $5.55 billion. Flex Ltd. sees Q3 2021 EPS of $0.34-$0.40. Flex Ltd. sees Q3 2021 revenue of $6-6.4 billion.

Mohawk Industries (NYSE: MHK) 11.5% HIGHER; reported Q3 EPS of $2.87, $0.73 better than the analyst estimate of $2.14. Revenue for the quarter came in at $2.57 billion versus the consensus estimate of $2.49 billion.

Zendesk (NYSE: ZEN) 8.5% HIGHER; reported Q3 EPS of $0.18, $0.07 better than the analyst estimate of $0.11. Revenue for the quarter came in at $261.9 million versus the consensus estimate of $253.74 million. Zendesk sees Q4 2020 revenue of $274-279 million, versus the consensus of $273.6 million. Zendesk sees FY2020 revenue of $1.02-1.025 billion, versus the consensus of $1.01 billion.

Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) 7.8% HIGHER; reported Q3 EPS of $16.40, $5.11 better than the analyst estimate of $11.29. Revenue for the quarter came in at $46.2 billion versus the consensus estimate of $42.9 billion.

Apple (NASDAQ: AAPL) 5.3% LOWER; reported Q4 EPS of $0.73, $0.03 better than the analyst estimate of $0.70. Revenue for the quarter came in at $64.7 billion versus the consensus estimate of $63.7 billion. The company is not providing first-quarter guidance, citing too much uncertainty due to COVID. iPhone sales of $26.444 billion for the quarter, missed the consensus of $27.06 billion. Services revenue of $14.549 billion, versus $12.511 billion last year.

Atlassian (NASDAQ: TEAM) 4.7% LOWER; reported Q1 EPS of $0.30, $0.03 better than the analyst estimate of $0.27. Revenue for the quarter came in at $459.5 million versus the consensus estimate of $440.41 million.

Skechers USA (NYSE: SKX) 4% LOWER; reported Q3 EPS of $0.53, $0.17 better than the analyst estimate of $0.36. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.22 billion.

Aspen Aerogels (NYSE: ASPN) 2% HIGHER; reported Q3 EPS of ($0.25), $0.09 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $24.2 million versus the consensus estimate of $26.28 million.

Activision Blizzard (NASDAQ: ATVI) 1.3% LOWER; reported Q3 EPS of $0.71, $0.06 better than the analyst estimate of $0.65. Revenue for the quarter came in at $1.77 billion versus the consensus estimate of $1.69 billion. Activision Blizzard sees Q4 2020 EPS of $1.09, versus the consensus of $1.08. Activision Blizzard sees Q4 2020 revenue of $2.73 billion, versus the consensus of $2.63 billion.